{"id":24612,"date":"2024-10-01T11:20:35","date_gmt":"2024-10-01T16:20:35","guid":{"rendered":"https:\/\/www.cornerstone.com\/?post_type=event&#038;p=24612"},"modified":"2024-10-01T11:20:35","modified_gmt":"2024-10-01T16:20:35","slug":"pharma-law-usa","status":"publish","type":"event","link":"https:\/\/www.cornerstone.com\/insights\/events\/pharma-law-usa\/","title":{"rendered":"Pharma Law USA"},"content":{"rendered":"","protected":false},"featured_media":3270,"template":"","categories":[66,65],"tags":[],"asset_type":[33],"class_list":["post-24612","event","type-event","status-publish","has-post-thumbnail","hentry","category-healthcare","category-life-sciences"],"acf":[],"yoast_head":"\n<title>Pharma Law USA | Cornerstone Research<\/title>\n<meta name=\"description\" content=\"Benjamin Fuller of Cornerstone Research will discuss the 340B drug program at this conference hosted by Informa Connect in Boston.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cornerstone.com\/insights\/events\/pharma-law-usa\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma Law USA\" \/>\n<meta property=\"og:description\" content=\"Benjamin Fuller of Cornerstone Research will discuss the 340B drug program at this conference hosted by Informa Connect in Boston.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cornerstone.com\/insights\/events\/pharma-law-usa\/\" \/>\n<meta property=\"og:site_name\" content=\"Cornerstone Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/CornerstoneResearchInc\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cornerstone.com\/wp-content\/uploads\/2024\/02\/Benjamin-Fuller.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@Cornerstone_Res\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cornerstone.com\/insights\/events\/pharma-law-usa\/\",\"url\":\"https:\/\/www.cornerstone.com\/insights\/events\/pharma-law-usa\/\",\"name\":\"Pharma Law USA | Cornerstone Research\",\"isPartOf\":{\"@id\":\"https:\/\/www.cornerstone.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cornerstone.com\/insights\/events\/pharma-law-usa\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cornerstone.com\/insights\/events\/pharma-law-usa\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cornerstone.com\/wp-content\/uploads\/2024\/02\/Benjamin-Fuller.png\",\"datePublished\":\"2024-10-01T16:20:35+00:00\",\"dateModified\":\"2024-10-01T16:20:35+00:00\",\"description\":\"Benjamin Fuller of Cornerstone Research will discuss the 340B drug program at this conference hosted by Informa Connect in Boston.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cornerstone.com\/insights\/events\/pharma-law-usa\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cornerstone.com\/insights\/events\/pharma-law-usa\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.cornerstone.com\/insights\/events\/pharma-law-usa\/#primaryimage\",\"url\":\"https:\/\/www.cornerstone.com\/wp-content\/uploads\/2024\/02\/Benjamin-Fuller.png\",\"contentUrl\":\"https:\/\/www.cornerstone.com\/wp-content\/uploads\/2024\/02\/Benjamin-Fuller.png\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cornerstone.com\/insights\/events\/pharma-law-usa\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cornerstone.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharma Law USA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cornerstone.com\/#website\",\"url\":\"https:\/\/www.cornerstone.com\/\",\"name\":\"Cornerstone Research\",\"description\":\"Economic and Financial Consulting and Expert Testimony\",\"publisher\":{\"@id\":\"https:\/\/www.cornerstone.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cornerstone.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cornerstone.com\/#organization\",\"name\":\"Cornerstone Research\",\"url\":\"https:\/\/www.cornerstone.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.cornerstone.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cornerstone.com\/wp-content\/uploads\/2022\/01\/Cornerstone-Research-Logo.jpg\",\"contentUrl\":\"https:\/\/www.cornerstone.com\/wp-content\/uploads\/2022\/01\/Cornerstone-Research-Logo.jpg\",\"width\":1000,\"height\":61,\"caption\":\"Cornerstone Research\"},\"image\":{\"@id\":\"https:\/\/www.cornerstone.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/CornerstoneResearchInc\",\"https:\/\/x.com\/Cornerstone_Res\",\"https:\/\/www.linkedin.com\/company\/cornerstone-research\/\"]}]}<\/script>\n","yoast_head_json":{"title":"Pharma Law USA | Cornerstone Research","description":"Benjamin Fuller of Cornerstone Research will discuss the 340B drug program at this conference hosted by Informa Connect in Boston.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cornerstone.com\/insights\/events\/pharma-law-usa\/","og_locale":"en_US","og_type":"article","og_title":"Pharma Law USA","og_description":"Benjamin Fuller of Cornerstone Research will discuss the 340B drug program at this conference hosted by Informa Connect in Boston.","og_url":"https:\/\/www.cornerstone.com\/insights\/events\/pharma-law-usa\/","og_site_name":"Cornerstone Research","article_publisher":"https:\/\/www.facebook.com\/CornerstoneResearchInc","og_image":[{"width":1200,"height":800,"url":"https:\/\/www.cornerstone.com\/wp-content\/uploads\/2024\/02\/Benjamin-Fuller.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@Cornerstone_Res","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cornerstone.com\/insights\/events\/pharma-law-usa\/","url":"https:\/\/www.cornerstone.com\/insights\/events\/pharma-law-usa\/","name":"Pharma Law USA | Cornerstone Research","isPartOf":{"@id":"https:\/\/www.cornerstone.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cornerstone.com\/insights\/events\/pharma-law-usa\/#primaryimage"},"image":{"@id":"https:\/\/www.cornerstone.com\/insights\/events\/pharma-law-usa\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cornerstone.com\/wp-content\/uploads\/2024\/02\/Benjamin-Fuller.png","datePublished":"2024-10-01T16:20:35+00:00","dateModified":"2024-10-01T16:20:35+00:00","description":"Benjamin Fuller of Cornerstone Research will discuss the 340B drug program at this conference hosted by Informa Connect in Boston.","breadcrumb":{"@id":"https:\/\/www.cornerstone.com\/insights\/events\/pharma-law-usa\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cornerstone.com\/insights\/events\/pharma-law-usa\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.cornerstone.com\/insights\/events\/pharma-law-usa\/#primaryimage","url":"https:\/\/www.cornerstone.com\/wp-content\/uploads\/2024\/02\/Benjamin-Fuller.png","contentUrl":"https:\/\/www.cornerstone.com\/wp-content\/uploads\/2024\/02\/Benjamin-Fuller.png","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/www.cornerstone.com\/insights\/events\/pharma-law-usa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cornerstone.com\/"},{"@type":"ListItem","position":2,"name":"Pharma Law USA"}]},{"@type":"WebSite","@id":"https:\/\/www.cornerstone.com\/#website","url":"https:\/\/www.cornerstone.com\/","name":"Cornerstone Research","description":"Economic and Financial Consulting and Expert Testimony","publisher":{"@id":"https:\/\/www.cornerstone.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cornerstone.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.cornerstone.com\/#organization","name":"Cornerstone Research","url":"https:\/\/www.cornerstone.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.cornerstone.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.cornerstone.com\/wp-content\/uploads\/2022\/01\/Cornerstone-Research-Logo.jpg","contentUrl":"https:\/\/www.cornerstone.com\/wp-content\/uploads\/2022\/01\/Cornerstone-Research-Logo.jpg","width":1000,"height":61,"caption":"Cornerstone Research"},"image":{"@id":"https:\/\/www.cornerstone.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/CornerstoneResearchInc","https:\/\/x.com\/Cornerstone_Res","https:\/\/www.linkedin.com\/company\/cornerstone-research\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.cornerstone.com\/wp-json\/wp\/v2\/event\/24612","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cornerstone.com\/wp-json\/wp\/v2\/event"}],"about":[{"href":"https:\/\/www.cornerstone.com\/wp-json\/wp\/v2\/types\/event"}],"version-history":[{"count":1,"href":"https:\/\/www.cornerstone.com\/wp-json\/wp\/v2\/event\/24612\/revisions"}],"predecessor-version":[{"id":24613,"href":"https:\/\/www.cornerstone.com\/wp-json\/wp\/v2\/event\/24612\/revisions\/24613"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cornerstone.com\/wp-json\/wp\/v2\/media\/3270"}],"wp:attachment":[{"href":"https:\/\/www.cornerstone.com\/wp-json\/wp\/v2\/media?parent=24612"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cornerstone.com\/wp-json\/wp\/v2\/categories?post=24612"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cornerstone.com\/wp-json\/wp\/v2\/tags?post=24612"},{"taxonomy":"asset_type","embeddable":true,"href":"https:\/\/www.cornerstone.com\/wp-json\/wp\/v2\/asset_type?post=24612"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}